Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient

Abstract

Many chemotherapeutic agents have been associated with drug-induced colitis (DIC). With newer agents' expansion of approval as first-line therapy for common cancers, it is important to be cognizant of their association with DIC. We present a case of brentuximab-associated DIC in an elderly woman with CD301 Hodgkin lymphoma. Brentuximab's association with DIC was suspected by others in the literature, but a history of stem-cell transplant in them would blur the association with graft-vs-host disease. Lack of stem-cell transplant in our patient makes the link between brentuximab and DIC unambiguous.

Complications of Brentuximab Therapy in Patients with Hodgkin’s Lymphoma and Concurrent Autoimmune Pathology—A Case Series

“…Crohn’s disease (CD), together with Ulcerative Colitis (UC), are recognized as the main two representatives of the inflammatory bowel disease spectrum [ 21 ]. As a general definition, these diseases are considered to develop in susceptible individuals as a result of the complex interactions between environmental factors, microbiome, and an abnormal immune system.…”